EUVIMEDEUVIMED entdecken
Open Access

Proteomic Profiling of Medullary Thyroid Cancer Identifies CAPN1 as a Key Regulator of NF1 and RET Fueled Growth

Eshan Khan, Hannah Hylton, Neel Rajan, Stephanie J Bouley, Jalal K Siddiqui, Swetha Rajasekaran, Ganesh R Koshre, Hayden Storts iD, Anisley Valenciaga, Misbah Khan, Sandya Liyanarachchi, Francisco Fernandez und 7 weitere

Thyroid® · 2025

DOI: 10.1089/thy.2024.0102 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thyroid®, 2025. Verfasst von Eshan Khan und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Biology and Genetics, The Ohio State University, Columbus, Ohio, USA. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Proto-Oncogene Proteins c-ret, Carcinoma, Neuroendocrine, Calpain. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Medullary thyroid cancer (MTC) is a frequently metastatic tumor of the thyroid that develops from the malignant transformation of C-cells. These tumors most commonly have activating mutations within the RET or RAS proto-oncogenes. Germline mutations within RET result in C-cell hyperplasia, and cause the MTC pre-disposition disorder, multiple endocrine neoplasia, type 2A (MEN2A). Single-agent therapies for MTC, including vandetanib (VAN) and cabozantinib for all MTCs and selpercatinib (SEL) for RET-mutated MTC, lead to partial responses but are not curative.

Methods

To identify new therapeutic targets for MTC, we conducted proteomic profiling of normal C-cells, MTC cells, pre-malignant MEN2A patient samples, and MTC tumors.

Results

From this analysis, we identified CAPN1, a member of the CALPAIN (CAPN) family endopeptidases, as widely upregulated in MTC samples. We found that short hairpin RNA-mediated depletion of CAPN1 or inhibitors of CAPN1 significantly reduced MTC cell growth, colony formation, and xenograft tumor growth in vivo . In addition, we show that CAPN1 inhibitors synergize with VAN and SEL in vitro , maximizing apoptosis. Mechanistic experiments implicate CAPN1 in inhibiting neurofibromin, encoded by NF1, and CAPN1 inhibitors stabilize NF1 protein levels and diminish downstream RAS/RET activation of AKT and ERK.

Conclusions

Our data suggest that increased CAPN1 levels support RET and RAS-fueled growth by reducing NF1 levels. We find that combinatorial therapies between CAPN1 inhibitors and VAN or SEL show maximal efficacy in MTC cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid NeoplasmsProto-Oncogene Proteins c-retCarcinoma, NeuroendocrineCalpainNeurofibromin 1HumansAnimalsProteomicsMiceCell Line, TumorCell ProliferationFemaleMultiple Endocrine Neoplasia Type 2aGene Expression Regulation, NeoplasticPiperidinesQuinazolines

Stichwörter der Autor:innen

CAPN1NF1RETmedullary thyroid cancerproteomicsselpercatinibvandetanib

Substanzen

Proto-Oncogene Proteins c-retCalpainRET protein, humanNeurofibromin 1CAPN1 protein, humanNF1 protein, humanvandetanibPiperidinesQuinazolines

Autor:innen und Institutionen

  • Department of Cancer Biology and Genetics, The Ohio State University, Columbus, Ohio, USA.
  • The Ohio State University Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA.
  • Department of Molecular Medicine and Therapeutics, The Ohio State University, Columbus, Ohio, USA.
  • Center for Genomic Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Division of Surgical Oncology, Ohio State University Comprehensive Cancer Center and Ohio State University Wexner Medical Center, Columbus, Ohio, USA.

ORCID-Profile: Hayden Storts, John Phay, Priya H Dedhia, Jing Wang, Wayne O Miles

Förderung

  • NCI NIH HHS

Zitieren

APA

Khan, E., Hylton, H., Rajan, N., Bouley, S. J., Siddiqui, J. K., Rajasekaran, S., Koshre, G. R., Storts, H., Valenciaga, A., Khan, M., Liyanarachchi, S., Fernandez, F., Zheng, X., Phay, J., Dedhia, P. H., Wang, J., Walker, J. A., Ringel, M. D., & Miles, W. O. (2025). Proteomic Profiling of Medullary Thyroid Cancer Identifies CAPN1 as a Key Regulator of NF1 and RET Fueled Growth. Thyroid®. https://doi.org/10.1089/thy.2024.0102

Vancouver

Khan E, Hylton H, Rajan N, Bouley SJ, Siddiqui JK, Rajasekaran S, et al. Proteomic Profiling of Medullary Thyroid Cancer Identifies CAPN1 as a Key Regulator of NF1 and RET Fueled Growth. Thyroid®. 2025. doi:10.1089/thy.2024.0102

BibTeX
@article{Khan2025,
  author = {Khan, Eshan and Hylton, Hannah and Rajan, Neel and Bouley, Stephanie J and Siddiqui, Jalal K and Rajasekaran, Swetha and Koshre, Ganesh R and Storts, Hayden and Valenciaga, Anisley and Khan, Misbah and Liyanarachchi, Sandya and Fernandez, Francisco and Zheng, Xuguang and Phay, John and Dedhia, Priya H and Wang, Jing and Walker, James A and Ringel, Matthew D and Miles, Wayne O},
  title = {Proteomic Profiling of Medullary Thyroid Cancer Identifies CAPN1 as a Key Regulator of NF1 and RET Fueled Growth},
  journal = {Thyroid®},
  year = {2025},
  doi = {10.1089/thy.2024.0102}
}
Kostenlos starten →